Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Nanogel-Based Drug Delivery Technology to Improve UTI Treatment

By HospiMedica International staff writers
Posted on 14 Mar 2025

Urinary tract infections (UTIs) are not only widespread and costly but also highly debilitating, significantly impacting the quality of life for those affected. More...

The antibiotics commonly used to treat UTIs often require extended or repeated treatment to be effective, which can contribute to resistance and cause harmful side effects, particularly in organs like the kidneys. This highlights the need for more efficient, long-lasting treatments to improve overall health and well-being. Researchers have now explored a novel approach to directly deliver antibiotics, specifically gentamicin, to bladder tissue to more effectively treat UTIs. They developed nanogels combined with a unique peptide (a small protein) that aids in the drug's entry into the cells where bacteria are hiding. The results, published in Nanomedicine, show that this technique was highly effective in animal models of UTIs, clearing over 90% of the bacteria from the bladder.

Scientists from the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) found that nanogel technology could deliver significantly more gentamicin than traditional methods, with a 36% higher concentration inside cells. Furthermore, this approach exhibited low toxicity, causing minimal harm to the cells. The nanogels also release the drug quickly, which enhances its ability to kill bacteria in the bladder faster. The researchers believe this innovative approach provides a more effective treatment by targeting infected cells directly, minimizing side effects, and reducing the risk of antibiotic resistance. They also suggest that this nanogel-based drug delivery system could be applied to other medical conditions beyond UTIs.

“We prove not only that this technology is doable but could be very effective for future clinical use and can potentially lead towards an eventual cure of recurrent infections,” said the paper’s senior author Michael Schurr, PhD, associate professor in the Department of Immunology & Microbiology at the University of Colorado School of Medicine.

Related Links:
University of Colorado Anschutz Medical Campus


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Immobilization System
Cranial 4Pi Immobilization
X-Ray Generator
Advantage Plus Generators
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.